Pancreatic cancer |
Patients' blood |
Ultracentrifugation |
Glypican-1 |
Diagnosis |
59 |
Medium |
Ultracentrifugation |
CD151, ADAM1 and ADAM15 |
Prognosis |
91 |
Patients' plasma |
Ultracentrifugation |
MIF |
Prognosis and treatment |
60 |
Patients' serum |
Ultracentrifugation |
vimentin |
Diagnosis and treatment |
61 |
Melanoma |
Patients' plasma |
Ultracentrifugation |
TYRP2, VLA-4, HSP70, HSP90 and MET |
Prognosis and treatment |
92 |
Patients' serum |
Ultracentrifugation |
MIA and S100B |
Prognosis and diagnosis |
93 |
Lung cancer |
Urine |
Ultracentrifugation |
LRG1 |
Diagnosis |
94 |
Saliva |
Ultracentrifugation |
BPIFA1, CRNN, MUC5B, and IQGAP |
Detection |
95 |
Medium |
ExoQuick-TC™ kit |
Vasorin |
Treatment |
96 |
Patients' blood |
Ultracentrifugation |
LG3BP and PIGR |
Diagnosis |
97 |
Glioblastoma |
Medium |
Ultracentrifugation |
angiogenin, IL-6 and IL-8 |
Detection and diagnosis |
98 |
Gastric cancer |
Medium |
Ultracentrifugation |
EGFR |
Detection and diagnosis |
10 |
Colorectal cancer |
Patients' blood |
Ultracentrifugation |
CD147 |
Detection and diagnosis |
99 |
Patients' plasma |
ExoCapTM kit |
GPC1 |
Diagnosis and treatment |
100 |
Ovarian cancer |
Ascytic fluid |
Ultracentrifugation |
CD24 |
Diagnosis |
101 |
Ascitic Fluid |
Ultracentrifugation |
TGM2, U2AF1, U2AF2, and HNRHPU |
Diagnosis |
102 |
Cholangiocarcinoma |
Patients' blood |
Ultracentrifugation |
VNN1, CRP, FIBG, IGHA1, and A1AG1 |
Diagnosis |
97 |
Prostate cancer |
Urine |
Ultracentrifugation |
PCA3 |
Diagnosis and monitoring |
103 |
Glioma |
Cerebrospinal fluid |
Ultracentrifugation |
IL13QD |
Detection and recurrence |
104 |